CTLA4 and neoplasm: Excitingly, in mouse lung and melanoma models, SB-3CT, a small-molecule MMP2/9 inhibitor, has been shown to enhance PD-1 or CTLA-4 blockade responses by promoting anti-tumour immunity [200].